Sam Brusco, Associate Editor03.04.24
Medtronic has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool 2.0 bone tumor ablation system to treat painful bone metastases and benign bone tumors like osteoid osteoma.
The new design allows use of four internally cooled probes at the same time so two vertebral bodies can be ablated at once, or to create larger ablation zones in applications outside of the spine.
According to Medtronic, OsteoCool 2.0 is the most powerful bone tumor ablation on the market with 20W per channel, over twice the power of Stryker’s OptaBlate system. It also has the widest choice of probe sizes in the U.S. market.
The technology is backed by OPuS One, the largest study of RF ablation in bone metastases, which showed swift (within three days), significant, and sustained (through 12 months) improvements in pain relief for cancer patients.
“OsteoCool 2.0 is a welcome upgrade to our interventional portfolio and further cements our status as offering the most innovative and comprehensive pain management portfolio in the industry,” said David Carr, VP and GM, of Medtronic’s Pain Interventions business.
The company began a limited release and plans a broad U.S. market launch later this year.
The new design allows use of four internally cooled probes at the same time so two vertebral bodies can be ablated at once, or to create larger ablation zones in applications outside of the spine.
According to Medtronic, OsteoCool 2.0 is the most powerful bone tumor ablation on the market with 20W per channel, over twice the power of Stryker’s OptaBlate system. It also has the widest choice of probe sizes in the U.S. market.
The technology is backed by OPuS One, the largest study of RF ablation in bone metastases, which showed swift (within three days), significant, and sustained (through 12 months) improvements in pain relief for cancer patients.
“OsteoCool 2.0 is a welcome upgrade to our interventional portfolio and further cements our status as offering the most innovative and comprehensive pain management portfolio in the industry,” said David Carr, VP and GM, of Medtronic’s Pain Interventions business.
The company began a limited release and plans a broad U.S. market launch later this year.